Acute Myocardial Infarction (AMI)

Clinical Indications

Acute MI: STEMIs account for 30% to 45% of all AMIs. Subjects who experience an AMI are at substantial risk for recurrent infarction, angina, stroke, and sudden death. Early reperfusion is a well established factor in limiting myocardial damage. However, with reperfusion, blood flow to the ischemic tissue may still be impeded at the microvascular level, resulting in no reflow and, over time, extension of infarct. Several observational studies and case reports suggest that, as an adjunct to revascularization, that IABP improves clinical outcomes in subjects with acute STEMI.1

IABP in AMI:

  • Salvages ischemic and reperfused myocardium2
  • Promotes epicardial vessel reperfusion and recovery of the microcirculation2
  • Improves myocardial tissue perfusion and enhances LV functional recovery after AMI2
  • Accelerates LV functional recovery via regional wall motion and LVEF2

1 Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and StrokeStatistics Subcommittee. Circulation. 2006;113(6):e85-151. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA
2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51(2):210-247. Cohen M, Urban P, Christenson JT, et al. Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry. Eur Heart J. 2003;24(19):1763- 1770.

2 Cardiogenic shock current concepts and improving outcomes. H R Reynolds et al. Circulation 2008;117 :686-697

Acute Myocardial Infarction

Interventional Cardiology

Surgery

Resources

Percutaneous Cardiac Assist Devices

Contact Us